Assistant Solicitor General, Texas
Katie serves as an Assistant Solicitor General for the State of Texas. She previously practiced law at a firm in Washington, D.C. where she focused her legal practice on complex trial and appellate litigation, specializing in data privacy and biometric issues. Before that, Katie served as Chief Counsel to Senator Jeff Flake at the U.S. Senate Judiciary Committee and clerked for Judge Michael B. Brennan of the U.S. Court of Appeals for the Seventh Circuit. Katie graduated from Liberty University and the Antonin Scalia Law School at George Mason University. She is a member of The Federalist Society’s Litigation Practice Group Executive Committee.
Partner, Evans Fears & Shuttert LLP
Lee Mickus defends manufacturers and other business interests in product liability and tort lawsuits around the country, guiding cases through the discovery, trial, and appeal stages. He has successfully tried cases to juries in Colorado, Texas, California, New York, Puerto Rico, Montana and several other states.
Partner, Wagstaff Law Firm
David Wool represents clients in toxic tort, pharmaceutical and medical device litigation. In his practice at Andrus Wagstaff, David has been intricately involved in the several major litigations. David was appointed to the Plaintiff’s Steering Committee in multi-district litigation (MDL) 2642, In Re Fluoroquinolone Products Liability Litigation, by the Honorable John R. Tunheim to represent thousands of plaintiffs suffering from permanent and debilitating peripheral neuropathy. Additionally, David served a critical role in MDL 2741, In Re Roundup Products Liability Litigation, successfully arguing against the first motion to dismiss filed anywhere in the country setting the stage for continued litigation. David is admitted to practice before the United States District Court for the District of Colorado, and represents clients in nearly every state across the country.
David has extensive knowledge and experience in every step of the litigation process from drafting complaints, to organizing multi-district litigation and arguing dispositive motions in federal court.
As a Trial Attorney in various litigations, David has:
David has litigated in nearly every federal circuit, and has extensive knowledge of complex federal and state specific products liability law including Daubert, Federal preemption law and the Learned Intermediary Doctrine. He has extensive experience briefing these and related issues in the United States District Courts for the Southern District of West Virginia, the Northern District of California, the District of Minnesota and the Judicial Panel for Multi-District Litigation, among others.
David is a native of Montgomery, Alabama and a graduate of Colorado College and Vanderbilt University Law School. Prior to joining Andrus Wagstaff
Assistant Solicitor General, Texas
Katie serves as an Assistant Solicitor General for the State of Texas. She previously practiced law at a firm in Washington, D.C. where she focused her legal practice on complex trial and appellate litigation, specializing in data privacy and biometric issues. Before that, Katie served as Chief Counsel to Senator Jeff Flake at the U.S. Senate Judiciary Committee and clerked for Judge Michael B. Brennan of the U.S. Court of Appeals for the Seventh Circuit. Katie graduated from Liberty University and the Antonin Scalia Law School at George Mason University. She is a member of The Federalist Society’s Litigation Practice Group Executive Committee.
Partner, Evans Fears & Shuttert LLP
Lee Mickus defends manufacturers and other business interests in product liability and tort lawsuits around the country, guiding cases through the discovery, trial, and appeal stages. He has successfully tried cases to juries in Colorado, Texas, California, New York, Puerto Rico, Montana and several other states.
Partner, Wagstaff Law Firm
David Wool represents clients in toxic tort, pharmaceutical and medical device litigation. In his practice at Andrus Wagstaff, David has been intricately involved in the several major litigations. David was appointed to the Plaintiff’s Steering Committee in multi-district litigation (MDL) 2642, In Re Fluoroquinolone Products Liability Litigation, by the Honorable John R. Tunheim to represent thousands of plaintiffs suffering from permanent and debilitating peripheral neuropathy. Additionally, David served a critical role in MDL 2741, In Re Roundup Products Liability Litigation, successfully arguing against the first motion to dismiss filed anywhere in the country setting the stage for continued litigation. David is admitted to practice before the United States District Court for the District of Colorado, and represents clients in nearly every state across the country.
David has extensive knowledge and experience in every step of the litigation process from drafting complaints, to organizing multi-district litigation and arguing dispositive motions in federal court.
As a Trial Attorney in various litigations, David has:
David has litigated in nearly every federal circuit, and has extensive knowledge of complex federal and state specific products liability law including Daubert, Federal preemption law and the Learned Intermediary Doctrine. He has extensive experience briefing these and related issues in the United States District Courts for the Southern District of West Virginia, the Northern District of California, the District of Minnesota and the Judicial Panel for Multi-District Litigation, among others.
David is a native of Montgomery, Alabama and a graduate of Colorado College and Vanderbilt University Law School. Prior to joining Andrus Wagstaff
Milton R. Underwood Chair in Free Enterprise, Vanderbilt University Law School
Brian Fitzpatrick is the Milton R. Underwood Chair in Free Enterprise and Professor of Law at Vanderbilt Law School, where his research focuses on class action litigation, federal courts, judicial selection, and constitutional law. He is best known for his empirical studies of class action settlements as well as his book The Conservative Case for Class Actions (University of Chicago Press, 2019). Professor Fitzpatrick joined Vanderbilt's law faculty in 2007 after serving as the John M. Olin Fellow at New York University School of Law. He graduated first in his class from Harvard Law School and went on to clerk for Judge Diarmuid O'Scannlain on the U.S. Court of Appeals for the Ninth Circuit and Justice Antonin Scalia on the U.S. Supreme Court. After his clerkships, Professor Fitzpatrick practiced commercial and appellate litigation for several years at Sidley Austin in Washington, D.C., and served as Special Counsel for Supreme Court Nominations to U.S. Senator John Cornyn. Before earning his law degree, Fitzpatrick graduated summa cum laude with a bachelor's of science in chemical engineering from the University of Notre Dame. He has received the Hall-Hartman Outstanding Professor Award, which recognizes excellence in classroom teaching, for his Civil Procedure and Federal Courts courses.
Ms. Malini Moorthy has been Head of the Litigation Department of Bayer Corporation since July 30, 2014. When she left Pfizer Inc., Ms. Moorthy spent many years as a litigation associate at law firms in the United States and Canada, including the New York office of Salans, and Genest Murray Desbrisay Lamek and McCarthy Tetrault, both in Toronto. Before beginning her corporate law career, Ms. Moorthy served as Executive Director of Free the Children in Toronto, an international children’s organization dedicated to ending the exploitation of children and empowering them through leadership development and training. Ms. Moorthy serves as the chair of the Advisory Council of the Duke Law Distinguished Lawyers Series and is on the Board of Directors of the National Center for Law and Economic Justice. She received her bachelor’s degree with honors in political science and economics from the University of North Carolina at Chapel Hill, where she was a Morehead Scholar, and her law degree from Queen’s University in Ontario, Canada, where she was the editor of the Queen’s Law Review.
Tim has had a multifaceted and storied career. For many years, Tim was a national trial lawyer with the firm of Shook, Hardy and Bacon. He handled mass tort cases for pharmaceutical, medical device and chemical companies. Tim was lead counsel in a number of high-profile trials for clients around the country and served as lead counsel in a medical device MDL. While in private practice, he was named a Leading National Products Liability Lawyer by Chambers USA, one of the Top 500 Litigators in America by Lawdragon, and one of the Best Lawyers in America. Tim taught at the National Institute for Trial Advocacy for many years and was a frequent speaker on legal topics, trial tactics and litigation strategy.
In 2008, Tim was recruited to become General Counsel and Corporate Secretary of Boston Scientific, a multinational medical device company. While there, Tim served on the Company's Executive Committee and was responsible for worldwide management of the company's Legal organization, Global Compliance, Government Affairs, Aviation, Global Security and other functions. He was also heavily involved in diversity and inclusion initiatives, the Boston Scientific Leadership Academy and innovative outside counsel management initiatives. Over his years at Boston Scientific, Tim was repeatedly awarded for his performance. In 2013, he was recognized by The Legal 500 and named to the "Corporate Counsel 100" list, which identifies the top most powerful corporate legal advisers in the United States. In 2016 he was honored by The Burton Awards as a “Legend in Law.” In 2016, he was flattered to receive the Valued Ally Award from Diversity Best Practices for his work in advancing diversity and inclusion.
Tim's work and influence is not limited to his work at Shook, Hardy and Boston Scientific. He has also worked with a number of organizations. Tim was on the Board and Executive Committee of AdvaMed, the trade association for the medical device industry. He is active in the prestigious and invitation-only Federation of Defense & Corporate Counsel (FDCC), where he served as President and Chairman. He currently serves as President of Lawyers for Civil Justice (LCJ), a group interested in improving the civil justice system in the United States. He had been a member of the boards for DRI and the New England Legal Foundation.
Managing Director, Berkeley Research Group
Dan Troy is Managing Director and an expert witness on FDA matters at Berkeley Research Group. Previously he served as Chief Counsel of the US Food and Drug Administration and General Counsel of GlaxoSmithKline PLC.
Associate Professor of Law, Center for Intellectual Property and Entrepreneurship, University of Missouri School of Law
Professor Lietzan researches, writes, and teaches primarily in the areas of food and drug regulation, intellectual property, and administrative law. Some of her recent scholarship has focused on the nature and purpose of the new drug approval system, federal regulation of fecal microbiota transplantation, federal regulation of products derived from cannabis, the political economy of the Hatch-Waxman (generic drug) statute, and incentives to study already approved drugs for new uses. She is an award-winning teacher, and she has been an elected member of the American Law Institute since 2006.
Professor Lietzan brings to her scholarship and teaching eighteen years of private practice experience, eight of them as a partner in the food and drug group at Covington & Burling in Washington, DC. In practice, she handled a wide range of complex legal problems and broader legislative and regulatory policy questions affecting FDA-regulated companies. This work included lifecycle management and strategy issues, regulatory strategy and advocacy, white collar defense, congressional investigations, briefing in products liability cases, and international regulatory policy work. She was involved in every major amendment to the Federal Food, Drug, and Cosmetic Act (FDCA) between 1997 and 2014 and was deeply immersed for more than a decade in the development of the Biologics Price Competition and Innovation Act of 2010. She has been consistently identified by her peers in private practice as a “Best Lawyer in America” in the categories of FDA law (since 2013) and Biotechnology Law (since 2007).
Professor Lietzan has held one leadership position or another at the Food and Drug Law Institute (FDLI) since 2004, including a stint on its Board of Directors from 2008 to 2012. She also held leadership positions in the American Bar Association’s Section of Science and Technology Law for fourteen years.
Professor Lietzan received a bachelor’s degree from the University of North Carolina, where she graduated with honors in history. She holds a master’s degree in history from UCLA and a law degree with high honors from Duke Law School.
Assistant Solicitor General, Texas
Katie serves as an Assistant Solicitor General for the State of Texas. She previously practiced law at a firm in Washington, D.C. where she focused her legal practice on complex trial and appellate litigation, specializing in data privacy and biometric issues. Before that, Katie served as Chief Counsel to Senator Jeff Flake at the U.S. Senate Judiciary Committee and clerked for Judge Michael B. Brennan of the U.S. Court of Appeals for the Seventh Circuit. Katie graduated from Liberty University and the Antonin Scalia Law School at George Mason University. She is a member of The Federalist Society’s Litigation Practice Group Executive Committee.
Partner, Evans Fears & Shuttert LLP
Lee Mickus defends manufacturers and other business interests in product liability and tort lawsuits around the country, guiding cases through the discovery, trial, and appeal stages. He has successfully tried cases to juries in Colorado, Texas, California, New York, Puerto Rico, Montana and several other states.
Partner, Wagstaff Law Firm
David Wool represents clients in toxic tort, pharmaceutical and medical device litigation. In his practice at Andrus Wagstaff, David has been intricately involved in the several major litigations. David was appointed to the Plaintiff’s Steering Committee in multi-district litigation (MDL) 2642, In Re Fluoroquinolone Products Liability Litigation, by the Honorable John R. Tunheim to represent thousands of plaintiffs suffering from permanent and debilitating peripheral neuropathy. Additionally, David served a critical role in MDL 2741, In Re Roundup Products Liability Litigation, successfully arguing against the first motion to dismiss filed anywhere in the country setting the stage for continued litigation. David is admitted to practice before the United States District Court for the District of Colorado, and represents clients in nearly every state across the country.
David has extensive knowledge and experience in every step of the litigation process from drafting complaints, to organizing multi-district litigation and arguing dispositive motions in federal court.
As a Trial Attorney in various litigations, David has:
David has litigated in nearly every federal circuit, and has extensive knowledge of complex federal and state specific products liability law including Daubert, Federal preemption law and the Learned Intermediary Doctrine. He has extensive experience briefing these and related issues in the United States District Courts for the Southern District of West Virginia, the Northern District of California, the District of Minnesota and the Judicial Panel for Multi-District Litigation, among others.
David is a native of Montgomery, Alabama and a graduate of Colorado College and Vanderbilt University Law School. Prior to joining Andrus Wagstaff
Milton R. Underwood Chair in Free Enterprise, Vanderbilt University Law School
Brian Fitzpatrick is the Milton R. Underwood Chair in Free Enterprise and Professor of Law at Vanderbilt Law School, where his research focuses on class action litigation, federal courts, judicial selection, and constitutional law. He is best known for his empirical studies of class action settlements as well as his book The Conservative Case for Class Actions (University of Chicago Press, 2019). Professor Fitzpatrick joined Vanderbilt's law faculty in 2007 after serving as the John M. Olin Fellow at New York University School of Law. He graduated first in his class from Harvard Law School and went on to clerk for Judge Diarmuid O'Scannlain on the U.S. Court of Appeals for the Ninth Circuit and Justice Antonin Scalia on the U.S. Supreme Court. After his clerkships, Professor Fitzpatrick practiced commercial and appellate litigation for several years at Sidley Austin in Washington, D.C., and served as Special Counsel for Supreme Court Nominations to U.S. Senator John Cornyn. Before earning his law degree, Fitzpatrick graduated summa cum laude with a bachelor's of science in chemical engineering from the University of Notre Dame. He has received the Hall-Hartman Outstanding Professor Award, which recognizes excellence in classroom teaching, for his Civil Procedure and Federal Courts courses.
Ms. Malini Moorthy has been Head of the Litigation Department of Bayer Corporation since July 30, 2014. When she left Pfizer Inc., Ms. Moorthy spent many years as a litigation associate at law firms in the United States and Canada, including the New York office of Salans, and Genest Murray Desbrisay Lamek and McCarthy Tetrault, both in Toronto. Before beginning her corporate law career, Ms. Moorthy served as Executive Director of Free the Children in Toronto, an international children’s organization dedicated to ending the exploitation of children and empowering them through leadership development and training. Ms. Moorthy serves as the chair of the Advisory Council of the Duke Law Distinguished Lawyers Series and is on the Board of Directors of the National Center for Law and Economic Justice. She received her bachelor’s degree with honors in political science and economics from the University of North Carolina at Chapel Hill, where she was a Morehead Scholar, and her law degree from Queen’s University in Ontario, Canada, where she was the editor of the Queen’s Law Review.
Tim has had a multifaceted and storied career. For many years, Tim was a national trial lawyer with the firm of Shook, Hardy and Bacon. He handled mass tort cases for pharmaceutical, medical device and chemical companies. Tim was lead counsel in a number of high-profile trials for clients around the country and served as lead counsel in a medical device MDL. While in private practice, he was named a Leading National Products Liability Lawyer by Chambers USA, one of the Top 500 Litigators in America by Lawdragon, and one of the Best Lawyers in America. Tim taught at the National Institute for Trial Advocacy for many years and was a frequent speaker on legal topics, trial tactics and litigation strategy.
In 2008, Tim was recruited to become General Counsel and Corporate Secretary of Boston Scientific, a multinational medical device company. While there, Tim served on the Company's Executive Committee and was responsible for worldwide management of the company's Legal organization, Global Compliance, Government Affairs, Aviation, Global Security and other functions. He was also heavily involved in diversity and inclusion initiatives, the Boston Scientific Leadership Academy and innovative outside counsel management initiatives. Over his years at Boston Scientific, Tim was repeatedly awarded for his performance. In 2013, he was recognized by The Legal 500 and named to the "Corporate Counsel 100" list, which identifies the top most powerful corporate legal advisers in the United States. In 2016 he was honored by The Burton Awards as a “Legend in Law.” In 2016, he was flattered to receive the Valued Ally Award from Diversity Best Practices for his work in advancing diversity and inclusion.
Tim's work and influence is not limited to his work at Shook, Hardy and Boston Scientific. He has also worked with a number of organizations. Tim was on the Board and Executive Committee of AdvaMed, the trade association for the medical device industry. He is active in the prestigious and invitation-only Federation of Defense & Corporate Counsel (FDCC), where he served as President and Chairman. He currently serves as President of Lawyers for Civil Justice (LCJ), a group interested in improving the civil justice system in the United States. He had been a member of the boards for DRI and the New England Legal Foundation.
Managing Director, Berkeley Research Group
Dan Troy is Managing Director and an expert witness on FDA matters at Berkeley Research Group. Previously he served as Chief Counsel of the US Food and Drug Administration and General Counsel of GlaxoSmithKline PLC.
Admitting Expert Evidence Under Rule 702: By What Standard?
Kateland R. Jackson, Leah Lorber, Lee S. Mickus, David Wool
This webinar will host a debate over the pending amendments to Federal Rule of Evidence...
Admitting Expert Evidence Under Rule 702: By What Standard?
Kateland R. Jackson, Leah Lorber, Lee S. Mickus, David Wool
This webinar will host a debate over the pending amendments to Federal Rule of Evidence...
Admitting Expert Evidence Under Rule 702: By What Standard?
TeleforumTopics
A Recipe for A Better World; Nine Parts Innovation, One Part Regulation
“To protect the environment, our health, and promote the social good we have to live...
Are MDLs working? An Assessment of Centralization
Brian T. Fitzpatrick, Malini Moorthy, Timothy A. Pratt, Daniel E. Troy
Multidistrict litigation (“MDL”) accounts for nearly half of all civil cases in federal courts. Although...
Topics
Multidistrict Litigation (MDL) Conference Livestream
Tune into the Livestream during the event from 9:15 AM to 3:15 PM Eastern Time...
Are MDLs working? An Assessment of Centralization
Multidistrict Litigation (MDL) Conference
Washington, DCA Second Look at the CREATES Act: What’s Not Being Said
Erika Lietzan
Note from the Editor: This article critically discusses the CREATES Act, which is currently pending...
United Nations' final report on medicine access deeply flawed
On September 14, the United Nations’ High Level Panel on Access to Medicines released its...
Topics
The United Nations' Misguided Approach to Healthcare Access
Intellectual property (IP) protections promote innovation and spur research and development into life-saving drugs and...